122 related articles for article (PubMed ID: 32957696)
1. Stem Cells Secretome from Oral Tissue Could Represent a Promising Therapeutic Approach in COVID-19-Disease?
Diomede F; Marconi GD; Fonticoli L; Pizzicannella J; Trubiani O
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957696
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use.
Bari E; Ferrarotti I; Saracino L; Perteghella S; Torre ML; Corsico AG
Cells; 2020 Apr; 9(4):. PubMed ID: 32283815
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulation and Regeneration Properties of Dental Pulp Stem Cells: A Potential Therapy to Treat Coronavirus Disease 2019.
Zayed M; Iohara K
Cell Transplant; 2020; 29():963689720952089. PubMed ID: 32830527
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome.
Harrell CR; Jovicic BP; Djonov V; Volarevic V
Anal Cell Pathol (Amst); 2020; 2020():1939768. PubMed ID: 33274176
[TBL] [Abstract][Full Text] [Related]
5. MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment.
Wang XY
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4537-4538. PubMed ID: 32373992
[TBL] [Abstract][Full Text] [Related]
6. [Mesenchymal stem cells in therapy of coronavirus disease 2019 - a review].
Shi X; Yu L; Ding C
Sheng Wu Gong Cheng Xue Bao; 2020 Oct; 36(10):1979-1991. PubMed ID: 33169564
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment.
Jayaramayya K; Mahalaxmi I; Subramaniam MD; Raj N; Dayem AA; Lim KM; Kim SJ; An JY; Lee Y; Choi Y; Raj A; Cho SG; Vellingiri B
BMB Rep; 2020 Aug; 53(8):400-412. PubMed ID: 32731913
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stem cell research progress for the treatment of COVID-19.
Yao D; Ye H; Huo Z; Wu L; Wei S
J Int Med Res; 2020 Sep; 48(9):300060520955063. PubMed ID: 32972277
[TBL] [Abstract][Full Text] [Related]
9. Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19.
McGowan EM; Haddadi N; Nassif NT; Lin Y
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003377
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia?
Muraca M; Pessina A; Pozzobon M; Dominici M; Galderisi U; Lazzari L; Parolini O; Lucarelli E; Perilongo G; Baraldi E
J Control Release; 2020 Sep; 325():135-140. PubMed ID: 32622963
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not.
Akkoc T
Adv Exp Med Biol; 2020; 1298():167-176. PubMed ID: 32648245
[TBL] [Abstract][Full Text] [Related]
12. Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients.
Al-Khawaga S; Abdelalim EM
Stem Cell Res Ther; 2020 Oct; 11(1):437. PubMed ID: 33059757
[TBL] [Abstract][Full Text] [Related]
13. [Mesenchymal stem cells in the treatment of COVID-19-progress and challenges].
Wang J; Zou W; Liu J
Sheng Wu Gong Cheng Xue Bao; 2020 Oct; 36(10):1970-1978. PubMed ID: 33169563
[TBL] [Abstract][Full Text] [Related]
14. A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol.
Fragoso-Saavedra S; Iruegas-Nunez DA; Quintero-Villegas A; García-González HB; Nuñez I; Carbajal-Morelos SL; Audelo-Cruz BM; Arias-Martínez S; Caro-Vega Y; Calva JJ; Luqueño-Martínez V; González-Duarte A; Crabtree-Ramírez B; Crispín JC; Sierra-Madero J; Belaunzarán-Zamudio PF; Valdés-Ferrer SI
BMC Infect Dis; 2020 Oct; 20(1):765. PubMed ID: 33066761
[TBL] [Abstract][Full Text] [Related]
15. Rationale for the Use of Radiation-Activated Mesenchymal Stromal/Stem Cells in Acute Respiratory Distress Syndrome.
Tovar I; Guerrero R; López-Peñalver JJ; Expósito J; Ruiz de Almodóvar JM
Cells; 2020 Sep; 9(9):. PubMed ID: 32887260
[TBL] [Abstract][Full Text] [Related]
16. Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges.
Singh H; Kakkar AK; Chauhan P
Expert Rev Anti Infect Ther; 2020 Oct; 18(10):997-1003. PubMed ID: 32552044
[TBL] [Abstract][Full Text] [Related]
17. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells.
Shu L; Niu C; Li R; Huang T; Wang Y; Huang M; Ji N; Zheng Y; Chen X; Shi L; Wu M; Deng K; Wei J; Wang X; Cao Y; Yan J; Feng G
Stem Cell Res Ther; 2020 Aug; 11(1):361. PubMed ID: 32811531
[TBL] [Abstract][Full Text] [Related]
18. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
Santos J; Brierley S; Gandhi MJ; Cohen MA; Moschella PC; Declan ABL
Viruses; 2020 Jun; 12(7):. PubMed ID: 32629804
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal Stem Cell Secretome as an Emerging Cell-Free Alternative for Improving Wound Repair.
Ahangar P; Mills SJ; Cowin AJ
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987830
[TBL] [Abstract][Full Text] [Related]
20. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19.
Khoury M; Cuenca J; Cruz FF; Figueroa FE; Rocco PRM; Weiss DJ
Eur Respir J; 2020 Jun; 55(6):. PubMed ID: 32265310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
